MTHFR Genotype

Two small letter changes in a single gene can quietly shape how well your body handles folate, how much of a damaging amino acid called homocysteine builds up in your blood, and how you respond to certain medications. If you have ever wondered why a parent had an early stroke, why a pregnancy ran into trouble, or why a standard B vitamin barely moves your numbers, MTHFR (methylenetetrahydrofolate reductase) genetics may be part of the story.

This test reads the two most studied positions in the MTHFR gene, called C677T and A1298C. It will not by itself tell you whether you are sick or about to get sick, but it gives you a fixed piece of information you only need to learn once, then carry forward to interpret your folate, homocysteine, and cardiovascular numbers more accurately for the rest of your life.

What This Test Actually Reads

MTHFR is a protein in nearly every cell that turns dietary folate into its active form, called 5-methyltetrahydrofolate. That active folate is what your body uses to convert homocysteine into methionine, a building block for many other essential molecules. When the enzyme runs slowly, homocysteine tends to rise and folate-dependent reactions strain.

The test reports your genotype at two positions. At position 677, you are either CC (two normal copies), CT (one normal, one slower copy), or TT (two slower copies). At position 1298, you are AA, AC, or CC. The TT and the combined CT/AC patterns are the ones associated with the lowest enzyme activity, and they often go hand in hand with higher homocysteine when folate intake is low.

Heart Attack and Stroke Risk

The strongest cardiovascular signal comes from large studies of stroke in populations with low folate intake. In a prospective study of about 156,000 Chinese adults, the 677TT genotype was associated with higher stroke risk, particularly bleeding inside the brain. The same study did not show a clear link with heart attacks, which fits a broader pattern: MTHFR is more reliably tied to stroke than to coronary events.

Mendelian randomization and meta-analytic work add nuance. A pooled analysis of genetic studies and randomized trials found that in regions where the population gets little folate, the 677CT and TT genotypes raise homocysteine and stroke risk more visibly, while in folate-fortified countries the same genotypes carry a smaller burden. In other words, your environment partly decides how loud your genotype speaks.

At the level of individual disease, the T allele has been linked to coronary artery disease in updated meta-analyses, with abnormal lipid levels suggested as one path between the variant and the artery. In hypertensive adults, the TT genotype combined with low platelet count picked out the subgroup with the largest stroke risk reduction when treated with folic acid in clinical work tied to Chinese hypertension trials.

Homocysteine, Folate, and B Vitamin Status

Across studies, the 677TT genotype reliably comes with higher homocysteine and lower folate, and a blunted response to short courses of folic acid. A meta-analysis of folic acid intervention studies found that TT carriers start higher on homocysteine, end higher, and need more sustained or higher-dose folate to catch up with CC carriers. A large trial in women of childbearing age found genotype was an independent predictor of folate and homocysteine concentrations even on uniform supplementation.

Stacking variants matters. A study of multiple one-carbon metabolism genes found that the more risk variants someone carried across MTHFR and related enzymes, the higher their risk of folate deficiency. The MTHFR A1298C variant alone sometimes correlated with slightly higher serum folate, hinting that the two MTHFR positions do not behave identically.

Pregnancy and Fertility

MTHFR was first put on the map by neural tube defects. Maternal or infant 677TT roughly doubles the risk of spina bifida, with risk strongly modified by folate and B12 intake. In a Mexican case-control study, mothers with the 677TT genotype who also had higher serum folate had substantially lower risk of having a child with anencephaly compared to TT mothers with lower folate, a striking example of nutrition softening genetics.

Beyond neural tube defects, maternal and paternal MTHFR variants have been linked to preeclampsia, gestational hypertension, small-for-gestational-age babies, and spontaneous preterm birth. A meta-analysis of 44 studies confirmed the C677T link with preterm birth, particularly in Asian and Indian populations. In a retrospective cohort of more than 1,000 IVF/ICSI cycles, certain combined MTHFR genotypes were tied to lower oocyte maturation and poorer embryo quality, though live birth rates were not clearly affected.

In men, a study of more than 2,100 hypofertile Caucasian patients found C677T and A1298C variants extremely common, with the highest homocysteine levels in 677TT carriers and combined heterozygous patterns. Another Chinese case-control study of men found only a weak link between 677T and reduced sperm count or motility. A small interventional study suggested adequate B9 and B12 intake improved sperm parameters specifically in T-allele carriers.

Mental Health and the Brain

The 677TT genotype shows a modest but consistent statistical link to depression, schizophrenia, and bipolar disorder. A HuGE review estimated a modestly higher risk for these conditions, and a more recent meta-analysis confirmed C677T as significantly associated with schizophrenia and major depression, with a marginal A1298C link to depression. The gene shapes methylation reactions, which add or remove small chemical tags on DNA and proteins, that influence neurotransmitter pathways, but the size of any individual person's risk is small.

Cognitive findings are mixed. In Parkinson's disease, homocysteine matters for cognition while the MTHFR genotype alone does not. In multiple sclerosis, homocysteine is consistently higher than in controls but the 677C>T variant gives conflicting results across studies.

Other Disease Associations

MTHFR variants have been studied in dozens of other conditions. A meta-analysis tied 677T to higher venous thromboembolism risk, especially in Asian populations. A separate meta-analysis linked 677TT and 1298CC to non-alcoholic fatty liver disease. The 677T allele has been associated with bladder cancer in Asians, breast cancer subtype risk in southwestern China, and modest associations with several other cancers, often population-specific.

In type 2 diabetes, work in Tunisian patients found C677T and A1298C polymorphisms associated with retinopathy and other vascular complications. In hypertensive patients with preeclampsia, the 677TT genotype independently predicted impaired kidney function. A long-running African-American kidney study tied the 1298C variant to steeper decline in kidney filtration over time.

Not every signal is bad. A UK case-control study of adults found 677TT and 1298C variants associated with LOWER risk of adult acute leukemia. Updated meta-analyses now classify many earlier positive findings, including for gastric and colorectal cancer, as weak or population-specific. This is one of the reasons your MTHFR result is best read as a piece of context, not a verdict.

Why an Unexpected Result Is Not a Verdict

Carrying a so-called risk genotype does not mean disease is coming. Most associations sit in the modest range, apply unevenly across ethnic groups, and shrink substantially when folate intake is adequate. The TT genotype is most informative as a reason to check your homocysteine and folate, not as a diagnosis on its own.

The reverse is also true. If you carry two normal CC copies at position 677, you are not immune. Homocysteine still rises with low B12, low folate, kidney decline, certain medications, and aging. Your genotype tells you the floor your enzyme works from, not the ceiling other factors can push you to.

Ethnic Background Shapes Interpretation

The 677T allele is rare in African populations, intermediate in northern Europeans and southern Chinese, and common in Italians, Hispanics, and northern Chinese. The 1298C allele runs in roughly the opposite gradient across China. This matters because most of the strongest disease signals come from populations where the variant is common and folate intake is low. A TT genotype in someone with strong folate intake in a fortified country carries far less risk than the same genotype in a low-folate setting.

Why You Only Need to Test This Once

Your genotype does not change. Unlike a cholesterol or glucose number, this is a one-time read. What does change over time is the biology MTHFR influences, namely your homocysteine, folate, and B12 levels, and that is what you should track on a recurring basis. A reasonable cadence is to draw a baseline homocysteine and folate alongside this genotype, retest those nutrient and homocysteine markers in 3 to 6 months if you start a B-vitamin program, and at least annually thereafter.

Trending homocysteine is the practical use of your MTHFR result. If you are TT or compound heterozygous, expect that you may need more folate, methylfolate, or B12 than someone with a CC pattern to bring homocysteine into a healthier range. A randomized trial in healthy young women found folic acid more effective than methylfolate at lowering homocysteine in TT carriers, while both worked similarly in CC and CT carriers. A separate trial of methylfolate, P5P, and methylcobalamin in people with MTHFR, MTR, and MTRR variants showed homocysteine and LDL cholesterol both dropping, especially in homozygous carriers.

What to Do With an Unexpected Result

If you turn out to be 677TT or carry combined variants, the next step is not to start treating your genotype. It is to measure the biology your genotype influences. Order homocysteine, serum or red blood cell folate, vitamin B12, and consider kidney function (creatinine, eGFR), since impaired kidney clearance raises homocysteine independently of MTHFR.

Specific patterns suggest specific next moves. High homocysteine with low B12 points to a B12 absorption or intake problem and may warrant a methylmalonic acid check. High homocysteine with low folate suggests dietary or supplementation review. High homocysteine with normal folate and B12 should prompt a kidney workup and consideration of factors that raise homocysteine independently. If you are pregnant or trying to conceive, your obstetric clinician should know your genotype so folate and B vitamin needs can be tailored accordingly.

If you are on methotrexate for psoriasis, rheumatoid arthritis, or cancer, MTHFR genotype is also useful as a pharmacogenetic marker. Studies show the 677TT genotype is linked to higher homocysteine and increased risk of methotrexate toxicity, and folic acid co-treatment partially blunts this. Sharing your genotype with your rheumatologist or oncologist may shape monitoring and supplementation.

When Results Can Be Misleading

Because this is a DNA test, results do not shift with diet, exercise, recent illness, or time of day. The two real misinterpretation traps are not the test, they are the interpretation:

• Overweighting the genotype: A TT result is often described as if it guarantees high homocysteine, low folate, or disease. It does not. Many TT carriers with good folate intake have normal homocysteine and unremarkable health.
• Confusing this with rare severe MTHFR deficiency: A small number of people inherit two severely damaging mutations in the MTHFR gene, causing a serious metabolic disease with neurological symptoms in infancy or childhood. This is not what the common C677T and A1298C variants describe.
• Ignoring the rest of the picture: Homocysteine is shaped by B12, folate, kidney function, age, sex, and certain drugs. Reading your genotype without these other measurements gives you only a small slice of the picture.
• Applying findings from the wrong population: A study showing strong risk for a TT carrier in low-folate rural China may not translate to someone living in a folate-fortified country with a B vitamin-rich diet.

Who This Information Helps Most

This test gives you the most useful new information if you have a personal or family history of early stroke or venous clots, recurrent pregnancy loss or other adverse pregnancy outcomes, persistently high homocysteine on standard labs, plans for IVF or other assisted reproduction, or upcoming or current treatment with methotrexate. It is a single piece of fixed context that will shape how you and your clinician interpret your other lab work for years.